Febrile events including convulsions following the administration of four brands of 2010 and 2011 inactivated seasonal influenza vaccine in NZ infants and children: The importance of routine active safety surveillance

Vaccine

Volumn 30, Issue 33, 2012, Pages 4945-4952

  Petousis Harris, Helen ^a   Poole, Tracey ^a   Turner, Nikki ^a   Reynolds, Gary ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Febrile convulsion; Influenza vaccine; Vaccine reactogenicity; Vaccine safety

Indexed keywords

INFLUENZA VACCINE; PARACETAMOL;

ARTICLE; CHILD; CONTROLLED STUDY; DELIRIUM; DRUG SAFETY; ETHNICITY; FEBRILE CONVULSION; FEMALE; FEVER; HEADACHE; HUMAN; IMMUNIZATION; INFANT; INFANTILE HYPOTONIA; INFLUENZA VACCINATION; IRRITABILITY; LETHARGY; MAJOR CLINICAL STUDY; MALAISE; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; RIGOR; SCHOOL CHILD; SEASONAL INFLUENZA; SEIZURE; SEX DIFFERENCE; SIDE EFFECT; TREATMENT RESPONSE; VOMITING;

CHILD; CHILD, PRESCHOOL; DRUG TOXICITY; FEMALE; FEVER; HUMANS; INCIDENCE; INFANT; INFLUENZA VACCINES; INTERVIEWS AS TOPIC; MALE; NEW ZEALAND; RETROSPECTIVE STUDIES; SEIZURES;

EID: 84862771618     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.05.052     Document Type: Article

References (41)

1. Beyer W.E.P., Nauta J.J.P., Palache A.M., Giezeman K.M., Osterhaus A.D.M.E. Immunogenicity and safety of inactivated influenza vaccines in primed populations: a systematic literature review and meta-analysis. Vaccine 2011, 29(34):5785-5792.
2. Vellozzi C., Burwen D.R., Dobardzic A., Ball R., Walton K., Haber P., et al. Safety of trivalent inactivated influenza vaccines in adults: background for pandemic influenza vaccine safety monitoring. Vaccine 2009, 27(15):2114-2120.
3. McMahon A.W., Iskander J., Haber P., Chang S., Woo E.J., Braun M.M., et al. Adverse events after inactivated influenza vaccination among children less than 2 years of age: analysis of reports from the vaccine adverse event reporting system, 1990-2003. Pediatrics 2005, 115(February (2)):453-460.
4. Haber P., DeStefano F., Angulo F.J., Iskander J., Shadomy S.V., Weintraub E., et al. Guillain-Barre syndrome following influenza vaccination. JAMA 2004, 292(November (20)):2478-2481.
5. Hambidge S.J., Glanz J.M., France E.K., McClure D., Xu S., Yamasaki K., et al. Safety of trivalent inactivated influenza vaccine in children 6-23 months old. JAMA 2006, 296(October (16)):1990-1997.
6. France E.K., Glanz J.M., Xu S., Davis R.L., Black S.B., Shinefield H.R., et al. Safety of the trivalent inactivated influenza vaccine among children: a population-based study. Arch Pediatr Adolesc Med 2004, 158(November (11)):1031-1036.
7. Greene S.K., Kulldorff M., Lewis E.M., Li R., Yin R., Weintraub E.S., et al. Near real-time surveillance for influenza vaccine safety: proof-of-concept in the vaccine safety datalink project. Am J Epidemiol 2010, 171(January (2)):177-188.
8. Department of Health and Human Services. Center for Biologics Evaluation and Research, editor. Guidance for industry: clinical data needed to support the licensure of seasonal inactivated influenza vaccines. United States Food and Drug Administration; 2007.
9. Jefferson T., Rivetti A., Harnden A., Di Pietrantonj C., Demicheli V. Vaccines for preventing influenza in healthy children. Cochrane Database Syst Rev 2008, 2. (update of Cochrane Database Syst Rev. 2006;(1):CD004879; PMID: 16437500). Cochrane Database of Systematic Reviews 2008(2):CD004879.
10. Petrovsky N., Sajkov D. Pediatric influenza immunization. Expert Rev Vaccines 2011, 10(May (5)):567-570.
11. Petousis-Harris H., Poole T., Booy R., Turner N. Fever following administration of two inactivated influenza vaccines - a survey of parents of New Zealand infants and children 5 years of age and under. Vaccine 2011, 29:2933-2937.
12. Investigation into febrile reactions in young children following 2010 seasonal trivalent influenza vaccination 2010, Australian Government Therapeutic Goods Administration. Department of Health and Aging (Ed.).
13. Armstrong P.K., Dowse G.K., Effler P.V., Carcione D., Blyth C.C., Richmond P.C., et al. Epidemiological study of severe febrile reactions in young children in Western Australia caused by a 2010 trivalent inactivated influenza vaccine. BMJ Open 2011 2011, (May).
14. CSL Biotherapies (New Zealand) Ltd. Fluvax Product Datasheet. 2011 [cited 2012 16 May]. Available from: . http://www.medsafe.govt.nz/profs/Datasheet/SearchResult.asp.
15. Sanofi pasteur. Vaxigrip Product Datasheet. 2011 [cited 2012 16 May]. Available from: . http://www.medsafe.govt.nz/profs/Datasheet/SearchResult.asp.
16. GlaxoSmithKline NZ Ltd. Fluarix Product Datasheet. 2011 [cited 2012 16 May]. Available from: . http://www.medsafe.govt.nz/profs/Datasheet/SearchResult.asp.
17. Michael Marcy S., Kohl K.S., Dagan R., Nalin D., Blum M., Jones M.C., et al. Fever as an adverse event following immunization: case definition and guidelines of data collection, analysis, and presentation. Vaccine 2004, 22(5-6):551-556.
18. Van den Berg B.J., Yerushalmy J. Studies on convulsive disorders in young children: incidence of Febrile and Nonfebrile convulsions by age and other factors. Pediatr Res 1969, 3(4):298-304.
19. Hauser W.A., The Prevalence Incidence of Convulsive Disorders in Children. Epilepsia 1994, 35:S1-S6.
20. Polkinghorne B.G., Muscatello D.J., MacIntyre C.R., Lawrence G.L., Middleton P.M., Torvaldsen S. Relationship between the population incidence of febrile convulsions in young children in Sydney Australia and seasonal epidemics of influenza and respiratory syncytial virus, 2003-2010: a time series analysis. BMC Infect Dis 2011, 11(October).
21. Harder K.M., Mølbak K., Glismann S., Christiansen A.H. Influenza-associated illness is an important contributor to febrile convulsions in Danish children. J Infect 2012, 64(5):520-524.
22. Nolan T., Richmond P.C., McVernon J., Skeljo M.V., Hartel G.F., Bennet J., et al. Safety and immunogenicity of an inactivated thiomersal-free influenza vaccine in infants and children. Influenza Other Respir Viruses 2009, 3:315-325.
23. CSL Limited Alfuria Package Insert. Available at: [accessed 14.02.10]. http://wwwfdagov/downloads/biologicsbloodvaccines/vaccines/approvedproducts/ucm220730pdf.
24. Hambidge S.J., Glanz J.M., France E.K., McClure D., Xu S., Yamasaki K., et al. Safety of trivalent inactivated influenza vaccine in children 6 to 23 months old. JAMA 2006, 296(October (16)):1990-1997.
25. Seasonal flu vaccines: no evidence of an increased risk of febrile convulsions in children 2010, Medicines and Healthcare Products Regulatory Agency, London. Department of Health (Ed.).
26. Wood N., Sheppeard V., Cashman P., Palasanthiran P., Casacelli M., Cannings K., et al. Influenza Vaccine Safety in Children less than 5 years old: the 2010 and 2011 experience in Australia. Pediatr Infect Dis 2012, 31(2):199-202. 10.1097/INF.0b013e31823d5303.
27. Tse A., Tseng H.F., Greene S.K., Vellozzi C., Lee G.M. Signal identification and evaluation for risk of febrile seizures in children following trivalent inactivated influenza vaccine in the Vaccine Safety Datalink Project, 2010-2011. Vaccine 2012, 30(11):2024-2031.
28. ACIP., Grp A.I.W. Update: Recommendations of the Advisory Committee on Immunization Practices (ACIP) regarding use of CSL Seasonal Influenza Vaccine (Afluria) in the United States during 2010-11. JAMA 2010, 304(December (21)):2353-2355. (Reprinted from MMWR, vol. 59, pg 989-992, 2010).
29. Webster R.G., Laver W.G. Influenza virus subunit vaccines: immunogenicity and lack of toxicity for rabbits of ether- and detergent-disrupted virus. J Immunol (Baltimore, Md: 1950) 1966, 96(4):596-605.
30. Warbuton M.F. Desoxycholate-split influenza vaccines. Bull World Health Organ 1969, 41(3-5):639-641.
31. Skowronski D.M., De Serres G., Scheifele D., Russell M.L., Warrington R., Davies H.D., et al. Randomized, double-blind, placebo-controlled trial to assess the rate of recurrence of oculorespiratory syndrome following influenza vaccination among persons previously affected. Clin Infect Dis 2003, 37(October (8)):1059-1066.
32. Tannock G.A., Bryce D.A., Hensley M.J., Saunders N.A., Gillett R.S., Kennedy W.S. Responses to one or two doses of a deoxycholate subunit influenza vaccine in a primed population. Vaccine 1984, 2(1):100-106.
33. Kelly H.A., Skowronski D.M., Serres G.D., Effler P.V. Adverse events associated with 2010 CSL and other inactivated influenza vaccines. Med J Aust 2011, 195(6):318-320.
34. Food and Drug Administration (US). Inspections, compliance, enforcement, and criminal investigations. Warning letter to Commonwealth Serum Laboratories (CSL), Ltd. 6/15/11. 2011.
35. Maraskovsky E., Becher D., Koernig S., Dyson A., Morelli A.B., Barndem M., et al. Scientific investigations of trivalent influenza vaccine-induced adverse events in the paediatric population: role of innate immunity. Potential use of biomarkers of inflammation and of early immunological events to assess vaccine safety 2012, International Alliance for Biological Standardization, Baltimore, MD, USA.
36. Blyth C.C., Currie A.J., Wiertsema S.P., Conway N., Kirkham L.A.S., Fuery A., et al. Trivalent influenza vaccine and febrile adverse events in Australia, 2010: clinical features and potential mechanisms. Vaccine 2011, 29(32):5107-5113.
37. Wang L-Y., Hu C-T., Ho T-Y., Lin H.H. Geographic and ethnic variations of long-term efficacy and immunogenicity of hepatitis B vaccination in Hualien, a HBV hyperendemic area. Vaccine 2006, 24(20):4427-4432.
38. Pittman P.R., Gibbs P.H., Cannon T.L., Friedlander A.M. Anthrax vaccine: short-term safety experience in humans. Vaccine 2001, 20(5-6):972-978.
39. Christy C., Pichichero M.E., Reed G.F., Decker M.D., Anderson E.L., Rennels M.B. Effect of gender, race, and parental education on immunogenicity and reported reactogenicity of acellular and whole-cell pertussis vaccines. Pediatrics 1995, 96(September (3 (Pt 2))):584-587.
40. Petousis-Harris H. Factors associated with vaccine reactogenicity in school aged children and young adults following administration of two protein-based vaccines. PhD thesis Auckland: University of Auckland; 2012.
41. Institute of Environmental and Science Research Ltd Influenza surveillance in New Zealand 2010 2011, Institute of Environmental and Science Research Ltd, Wellington.